🎉🎉我們團隊的研究論文得到美國過敏氣喘與免疫醫學會特別以新聞快訊報導🎉🎉
Medication effects on acute exacerbation in asthma-COPD Overlap
10/10接到Journal of Allergy and Clinical Immunology的編輯部來信、#美國過敏氣喘與免疫醫學會把團隊的研究選為重點標示文章，將在寄送給所有學會會員新的電子月刊中，標註我們研究發現對臨床治療的重要性~
The editors of the Journal of Allergy and Clinical Immunology: In Practice and the AAAAI have selected your article, “Use of ICS/LABA Combinations or LAMA is Associated with a Lower Risk of Acute Exacerbation in Patients with Coexistent COPD and Asthma,” (17-00537) to be highlighted in Practice Matters, a new monthly email from the Academy of Allergy, Asthma & Immunology to its members, that specifically addresses topics that are important to allergists in practice.
回顧今年三月當時美國過敏氣喘與免疫醫學會網站上，用新聞快訊推廣我們的這一篇研究！
用研究讓世界看見台灣，本土研究能被AAAAI報導實屬難得，願與大家分享這份榮耀。
The editors of the Journal of Allergy and Clinical Immunology: In Practice and the AAAAI have selected your article, “Use of ICS/LABA Combinations or LAMA is Associated with a Lower Risk of Acute Exacerbation in Patients with Coexistent COPD and Asthma,” (17-00537) to be highlighted in Practice Matters, a new monthly email from the Academy of Allergy, Asthma & Immunology to its members, that specifically addresses topics that are important to allergists in practice.
回顧今年三月當時美國過敏氣喘與免疫醫學會網站上，用新聞快訊推廣我們的這一篇研究！
用研究讓世界看見台灣，本土研究能被AAAAI報導實屬難得，願與大家分享這份榮耀。
AAAAI: The American Academy of Allergy, Asthma & Immunology
(美國過敏氣喘與免疫醫學會)
沒有留言:
張貼留言